Articles from Caixin Global, Caixin Global

Caixin Global

Articles from Caixin Global

Caixin is a media group dedicated to providing financial and business news through periodicals, online content, mobile apps, conferences, books and TV/video programs. Caixin aims to blaze a trail that helps traditional media prosper in the new media age through integrated multimedia platforms.

News from Caixin

Cross Asset Strategy

<ul><li>Drug / State drugmaker snared over scheme to rip off government</li><li>Housing / China offers multiple-child families housing help as demographic crisis looms</li><li>Economy / China’s Li urges more pro-growth policy as economy sputters</li></ul>

Drug / State drugmaker snared over scheme to rip off governmentHousing / China offers multiple-child families housing help as demographic crisis loomsEconomy / China’s Li urges more pro-growth policy as economy sputters

CX Daily: State Drugmaker Snared Over Scheme to Rip Off Government

IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Equity Capital Markets

Zhihu Technology / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/zhihu-technology-ltd" target="_blank" data-smartkarma-citation="entities:32185:1" rel="noopener">Zhihu Technology (ZH US)</a> has launched an HKEx dual-primary listing to raise $150-200 million. The H Shares will be priced on 14 April and listed on 22 April.</li>
<li>In <a href="https://www.smartkarma.com/insights/zhihu-dual-primary-listing-a-question-of-judgment" target="_blank" data-smartkarma-citation="insights:68266" rel="noopener">Zhihu Dual-Primary Listing: A Question of Judgment</a>, we stated that while a loss-making tech name is not everybody's cup of tea, Zhihu has resilient performance and an undemanding valuation.  </li>
<li>In this note, we will look at Zhihu’s potential HK-ADS premium/(discount). Zhihu pricing its H-shares at a discount of 3-4% to its ADSs will be reasonable, in our view.</li>
</ul>



Zhihu Technology (ZH US) has launched an HKEx dual-primary listing to raise $150-200 million. The H Shares will be priced on 14 April and listed on 22 April.
In Zhihu Dual-Primary Listing: A Question of Judgment, we stated that while a loss-making tech name is not everybody's cup of tea, Zhihu has resilient performance and an undemanding valuation.  
In this note, we will look at Zhihu’s potential HK-ADS premium/(discount). Zhihu pricing its H-shares at a discount of 3-4% to its ADSs will be reasonable, in our view.


Zhihu Dual-Primary Listing: HK-ADS Premium/​​​(Discount) Views

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Alibaba Group Holding  / Equity Capital Markets

<ul>
<li>On 2nd Apr 2022, CSRC put out a draft for public comments on the revision of certain provisions which would allow easier access by overseas regulators to China ADRs audits.</li>
<li>On 8th Mar 2022, Securities Exchange Commission (SEC) had added five China ADR names to its provisional list of issuers under HFCAA, which set the clock ticking for their delisting.</li>
<li>In this note, we'll talk about the latest developments and its implications.</li>
</ul>


On 2nd Apr 2022, CSRC put out a draft for public comments on the revision of certain provisions which would allow easier access by overseas regulators to China ADRs audits.
On 8th Mar 2022, Securities Exchange Commission (SEC) had added five China ADR names to its provisional list of issuers under HFCAA, which set the clock ticking for their delisting.
In this note, we'll talk about the latest developments and its implications.


China ADRs Delisting - Tide Is Turning with CSRC Showing Signs of a Compromise

China and US Equity Analyst

Roger Xie

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/yum-china-holdings-inc" target="_blank" data-smartkarma-citation="entities:23677:1" rel="noopener">Yum China Holdings, Inc (YUMC US)</a> reported below-expectation 4Q21 earnings. Same store sale growth was down 11% year-over-year due to recent resurging of COVID cases in several regions of China.</li>
<li>Yum China has leveraged its digital orders and delivery service to alleviate the impacts. Based on its operation in 1Q20, we believe Yum China could recover quickly from current outbreak.</li>
<li>We think risk/reward is more compelling to own <a href="https://www.smartkarma.com/entities/yum-china-holdings-inc" target="_blank" data-smartkarma-citation="entities:23677:1" rel="noopener">Yum China Holdings, Inc (YUMC US)</a> as it has resilient business model and proven records to navigate through pandemic. </li>
</ul>



Yum China Holdings, Inc (YUMC US) reported below-expectation 4Q21 earnings. Same store sale growth was down 11% year-over-year due to recent resurging of COVID cases in several regions of China.
Yum China has leveraged its digital orders and delivery service to alleviate the impacts. Based on its operation in 1Q20, we believe Yum China could recover quickly from current outbreak.
We think risk/reward is more compelling to own Yum China Holdings, Inc (YUMC US) as it has resilient business model and proven records to navigate through pandemic. 


Yum China (YUMC.US/​9987.HK): Zero-COVID Policy Weighted on Earnings

<ul>
<li>The latest wave of COVID-19 infections cast a shadow on store traffic recovery for transportation hubs. Looking forward, there will likely more tightening preventive measurement into Chinese New Year.</li>
<li>
<a href="https://www.smartkarma.com/entities/yum-china-holdings-inc" target="_blank" data-smartkarma-citation="entities:23677:1" rel="noopener">Yum China Holdings, Inc (YUMC US)</a> has corrected 30% from its high since July due to the resurge of COVID cases in several cities in China 2nd half of year. </li>
<li>We think risk/reward is more compelling to own <a href="https://www.smartkarma.com/entities/yum-china-holdings-inc" target="_blank" data-smartkarma-citation="entities:23677:1" rel="noopener">Yum China Holdings, Inc (YUMC US)</a> as it has resilient business model and proven records to navigate through pandemic. </li>
</ul>


The latest wave of COVID-19 infections cast a shadow on store traffic recovery for transportation hubs. Looking forward, there will likely more tightening preventive measurement into Chinese New Year.

Yum China Holdings, Inc (YUMC US) has corrected 30% from its high since July due to the resurge of COVID cases in several cities in China 2nd half of year. 
We think risk/reward is more compelling to own Yum China Holdings, Inc (YUMC US) as it has resilient business model and proven records to navigate through pandemic. 


Yum China (YUMC.US/9987.HK): Resilient Business Model in the Face of Rising COVID Cases

China

Yum China Holdings, Inc. operates chain restaurants. The Company offers pizza, entrees, pasta, rice dishes, appetizers, soups, vegetables, beverages, and desserts. Yum China Holding conducts its business worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Yum China Holdings (9987 HK)

CX Daily: State Drugmaker Snared Over Scheme to Rip Off Government

State drugmaker snared over scheme to rip off government. China offers multiple-child families housing help as demographic crisis looms

Caixin Global

Zhihu Dual-Primary Listing: HK-ADS Premium/(Discount) Views

In this note, we will look at Zhihu’s potential HK-ADS premium/(discount). Zhihu pricing its H-shares at a discount of 3-4% to its ADSs will be...

Arun George

China ADRs Delisting - Tide Is Turning with CSRC Showing Signs of a Compromise

On 2nd Apr 2022, CSRC put out a draft for public comments on the revision of certain provisions which would allow easier access by overseas...

Sumeet Singh

Yum China (YUMC.US/9987.HK): Zero-COVID Policy Weighted on Earnings

Yum China reported disappointing 4Q21 earnings due to resurging of COVID cases in China. But we think risk/reward is more compelling as Yum China...

Roger Xie

Yum China (YUMC.US/9987.HK): Resilient Business Model in the Face of Rising COVID Cases

We think any share price weakness creates a good opportunity to accumulate Yum China. The risk/reward is more compelling given it has resilient...

Roger Xie

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

CX Daily: State Drugmaker Snared Over Scheme to Rip Off Government

State drugmaker snared over scheme to rip off government. China offers multiple-child families housing help as demographic crisis looms

Caixin Global

Zhihu Dual-Primary Listing: HK-ADS Premium/​​​(Discount) Views

In this note, we will look at Zhihu’s potential HK-ADS premium/(discount). Zhihu pricing its H-shares at a discount of 3-4% to its ADSs will be...

Arun George

China ADRs Delisting - Tide Is Turning with CSRC Showing Signs of a Compromise

On 2nd Apr 2022, CSRC put out a draft for public comments on the revision of certain provisions which would allow easier access by overseas...

Sumeet Singh

Yum China (YUMC.US/​9987.HK): Zero-COVID Policy Weighted on Earnings

Yum China reported disappointing 4Q21 earnings due to resurging of COVID cases in China. But we think risk/reward is more compelling as Yum China...

Roger Xie

Yum China (YUMC.US/9987.HK): Resilient Business Model in the Face of Rising COVID Cases

We think any share price weakness creates a good opportunity to accumulate Yum China. The risk/reward is more compelling given it has resilient...

Roger Xie

Zhihu Dual-Primary Listing: HK-ADS Premium/(Discount) Views

Yum China (YUMC.US/9987.HK): Zero-COVID Policy Weighted on Earnings